| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 8-K | 10-K | 8-K | 10-K | S-1 |
| Contract revenue | | | | | | |
| Operating expenses | | | | | | |
| Research and development | 36.6 | | 26.5 | | 12.0 | |
| General and administrative | 26.8 | 26.8 | 27.8 | 27.8 | 5.0 | 3.5 |
| Total operating expenses | 63.5 | 63.5 | 54.3 | 54.3 | 17.0 | 28.0 |
| Loss from operations | -63.5 | -63.5 | -51.6 | -51.6 | -16.5 | -27.1 |
| |
| Other income (expense), net | | | | | | |
| Interest income and other, net | 1.2 | | 0.1 | | | |
| |
| Loss on extinguishment of debt | | | | | | |
| Interest expense and other, net | -1.1 | | -0.5 | | -0.1 | |
| |
| Change in estimated fair value of preferred unit warrant | | | | | | |
| Loss before income taxes | -63.3 | | -53.0 | | -16.7 | |
| Income tax expense | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | |
| Net loss | -63.3 | | -53.1 | | -16.7 | |
| Net loss attributable to non-controlling interest | -32.8 | -32.8 | -44.8 | -44.8 | -16.7 | |
| Net loss attributable to Rani Therapeutics Holdings, Inc. | -30.6 | -63.3 | -8.3 | -53.1 | | |
| |
| Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., basic | ($1.28) | | ($0.43) | | | |
| Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted | ($1.28) | | ($0.43) | | | |
| |
| Weighted-average share outstanding basic | 23.8 | | 0.0 | | | |
| Weighted-average share outstanding diluted | 23.8 | | 19.5 | | | |